MA35180B1 - Utilisation d4un anticorps immunoconjugue de maytansinoide anti-cd19 pour le traitement de symptomes de malignites a lymphocytes b - Google Patents

Utilisation d4un anticorps immunoconjugue de maytansinoide anti-cd19 pour le traitement de symptomes de malignites a lymphocytes b

Info

Publication number
MA35180B1
MA35180B1 MA36558A MA36558A MA35180B1 MA 35180 B1 MA35180 B1 MA 35180B1 MA 36558 A MA36558 A MA 36558A MA 36558 A MA36558 A MA 36558A MA 35180 B1 MA35180 B1 MA 35180B1
Authority
MA
Morocco
Prior art keywords
maytansinoide
symptoms
treatment
cell malignancies
immunoconjugate antibody
Prior art date
Application number
MA36558A
Other languages
English (en)
Inventor
Rodica Morariu
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46085972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35180(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA35180B1 publication Critical patent/MA35180B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La présente invention concerne un immunoconjugué de maytansinoïde anti-cd19 qui est utilisé pour traiter un symptôme de malignités à lymphocytes b, en particulier un lymphome non hodgkinien.
MA36558A 2011-05-17 2013-12-12 Utilisation d4un anticorps immunoconjugue de maytansinoide anti-cd19 pour le traitement de symptomes de malignites a lymphocytes b MA35180B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11290232A EP2524929A1 (fr) 2011-05-17 2011-05-17 Utilisation d'anticorps immunoconjugués anti-CD19 maytansinoïdes pour le traitement de symptômes de malignités CD19+lymphocytes B
PCT/EP2012/059141 WO2012156455A1 (fr) 2011-05-17 2012-05-16 Utilisation d'un anticorps immunoconjugué de maytansinoïde anti-cd19 pour le traitement de symptômes de malignités à lymphocytes b

Publications (1)

Publication Number Publication Date
MA35180B1 true MA35180B1 (fr) 2014-06-02

Family

ID=46085972

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36558A MA35180B1 (fr) 2011-05-17 2013-12-12 Utilisation d4un anticorps immunoconjugue de maytansinoide anti-cd19 pour le traitement de symptomes de malignites a lymphocytes b

Country Status (30)

Country Link
US (2) US9555126B2 (fr)
EP (2) EP2524929A1 (fr)
JP (4) JP6050328B2 (fr)
KR (1) KR20140043388A (fr)
CN (2) CN103547596A (fr)
AR (1) AR086412A1 (fr)
AU (3) AU2012258254B2 (fr)
BR (1) BR112013029330A8 (fr)
CA (1) CA2835738A1 (fr)
CL (1) CL2013003272A1 (fr)
CO (1) CO6821893A2 (fr)
CR (1) CR20130593A (fr)
DO (1) DOP2013000260A (fr)
EA (1) EA028574B1 (fr)
EC (1) ECSP13013084A (fr)
GT (1) GT201300276A (fr)
IL (3) IL229380B (fr)
MA (1) MA35180B1 (fr)
MX (1) MX347019B (fr)
MY (1) MY163736A (fr)
NI (1) NI201300119A (fr)
PE (1) PE20141018A1 (fr)
PH (1) PH12017501368A1 (fr)
SG (2) SG194894A1 (fr)
TN (1) TN2013000468A1 (fr)
TW (3) TW201834687A (fr)
UA (1) UA114401C2 (fr)
UY (1) UY34077A (fr)
WO (1) WO2012156455A1 (fr)
ZA (1) ZA201309400B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2524929A1 (fr) * 2011-05-17 2012-11-21 Sanofi Utilisation d'anticorps immunoconjugués anti-CD19 maytansinoïdes pour le traitement de symptômes de malignités CD19+lymphocytes B
EP2777714A1 (fr) * 2013-03-15 2014-09-17 NBE-Therapeutics LLC Procédé de production d'un conjugué de ligand immunologique/charge utile à l'aide d'une enzyme transpeptidase spécifique pour une séquence
AU2014312086B2 (en) 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
CN105837689B (zh) * 2015-01-13 2020-06-19 博生吉安科细胞技术有限公司 抗cd19单克隆抗体及其制备方法
WO2016180941A1 (fr) * 2015-05-13 2016-11-17 Sanofi Compositions liquides pour conjugués médicament-anticorps anti-cd19
EP3603672A1 (fr) 2015-05-26 2020-02-05 MorphoSys AG Combinaison d'un anticorps anti-cd19 et d'un inhibiteur de la tyrosine kinase de bruton et utilisations de ceux-ci
LT3337506T (lt) 2015-08-21 2021-10-11 Morphosys Ag Deriniai ir jų panaudojimas
CN108601828B (zh) 2015-09-17 2023-04-28 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
US20170189548A1 (en) 2015-11-25 2017-07-06 Immunogen, Inc. Pharmaceutical formulations and methods of use thereof
EA201892542A1 (ru) 2016-05-30 2019-06-28 МорфоСис АГ Способы прогнозирования у пациентов терапевтического эффекта терапии с использованием антител к cd19
WO2018002031A1 (fr) 2016-06-27 2018-01-04 Morphosys Ag Formulations d'anticorps anti-cd19
RU2756405C2 (ru) 2016-10-28 2021-09-30 МорфоСис АГ Комбинация антитела CD19 с ингибитором BCL-2 и пути ее применения
WO2018183494A1 (fr) * 2017-03-31 2018-10-04 Immunogen, Inc. Conjugués anticorps-médicament ciblant cd19
BR112019021822A2 (pt) * 2017-04-20 2020-05-26 Adc Therapeutics Sa Terapia de combinação
BR112019026564A2 (pt) 2017-06-14 2020-06-30 Adc Therapeutics Sa regimes de dosagem para a administração de um adc anti-cd19
AU2018336520A1 (en) * 2017-09-21 2020-03-19 WuXi Biologics Ireland Limited Novel anti-CD19 antibodies
WO2019140141A1 (fr) 2018-01-12 2019-07-18 Immunogen, Inc. Procédés de production, purification et formulation de conjugués anticorps-médicaments
PT3958977T (pt) 2019-04-26 2023-12-15 Immunogen Inc Derivados de camptotecina
JP2022532519A (ja) 2019-05-03 2022-07-15 モルフォシス・アーゲー 限られた数のｎｋ細胞を有する患者における抗ｃｄ１９療法
WO2021084063A1 (fr) 2019-10-31 2021-05-06 Morphosys Ag Polythérapie antitumorale comprenant un anticorps anti-cd19 et des lymphocytes t gamma-delta
CN114599392A (zh) * 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗
JP2023501209A (ja) 2019-10-31 2023-01-18 モルフォシス・アーゲー 白血病またはリンパ腫の治療のためのレナリドミドと組み合わせた抗ｃｄ１９療法
CN110845617B (zh) * 2019-12-05 2021-07-09 常州费洛斯药业科技有限公司 针对cd19的全人源抗体或抗体片段、嵌合抗原受体及应用
JP2023530499A (ja) 2020-06-22 2023-07-18 モルフォシス・アーゲー 抗ＣＤ１９抗体及びＳＩＲＰα－ＣＤ４７自然免疫チェックポイントを遮断するポリペプチドを含む抗腫瘍組み合わせ療法
KR20230104152A (ko) 2020-10-06 2023-07-07 젠코어 인코포레이티드 전신 홍반성 루푸스(sle)를 포함하는 자가면역 질환을 치료하기 위한 바이오마커, 방법 및 조성물
EP4255480A2 (fr) 2020-12-04 2023-10-11 MorphoSys AG Polythérapie anti-cd19
WO2023073645A1 (fr) 2021-10-29 2023-05-04 Takeda Pharmaceutical Company Limited Thérapie avec un anticorps anti-cd19 et un inhibiteur enzymatique activateur de sumo
WO2024038115A1 (fr) 2022-08-17 2024-02-22 Morphosys Ag Thérapie comprenant un anticorps anti-cd19 et des modulateurs d'ezh2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229960B2 (en) * 2000-11-03 2007-06-12 University Of Vermont And State Agricultural College Methods and compositions for inhibiting GRB7
CA2525130C (fr) * 2003-05-20 2014-04-15 Immunogen, Inc. Agents cytotoxiques ameliores contenant de nouveaux maytansinoides
PL2066349T3 (pl) * 2006-09-08 2012-09-28 Medimmune Llc Humanizowane przeciwciała anty-CD19 i ich zastosowanie w leczeniu nowotworów, transplantacjach i leczeniu chorób autoimmunologicznych
CA3014224C (fr) * 2009-02-05 2022-05-24 Immunogen, Inc. Derives de benzodiazepine-indoline et procedes de preparation des derives
NZ613647A (en) * 2009-05-06 2015-02-27 Biotest Ag Uses of immunoconjugates targeting cd138
JP2013508400A (ja) * 2009-10-21 2013-03-07 イミュノジェン・インコーポレーテッド 新規な投与レジメンおよび治療法
EP2524929A1 (fr) * 2011-05-17 2012-11-21 Sanofi Utilisation d'anticorps immunoconjugués anti-CD19 maytansinoïdes pour le traitement de symptômes de malignités CD19+lymphocytes B
EP2550975A1 (fr) * 2011-07-29 2013-01-30 Sanofi Polythérapie pour le traitement de symptômes de malignités CD19+lymphocytes B comprenant un immunoconjugué anti-CD19 maytansinoïde et du rituximab

Also Published As

Publication number Publication date
US20140072587A1 (en) 2014-03-13
TW201726167A (zh) 2017-08-01
EA028574B1 (ru) 2017-12-29
UA114401C2 (uk) 2017-06-12
GT201300276A (es) 2015-03-23
NI201300119A (es) 2014-02-28
IL229380B (en) 2018-02-28
US20170196988A1 (en) 2017-07-13
JP2014515036A (ja) 2014-06-26
AR086412A1 (es) 2013-12-11
CO6821893A2 (es) 2013-12-31
PE20141018A1 (es) 2014-08-27
MX347019B (es) 2017-04-07
AU2016206317A1 (en) 2016-08-11
DOP2013000260A (es) 2014-01-31
JP6050328B2 (ja) 2016-12-21
AU2012258254A1 (en) 2013-05-02
WO2012156455A1 (fr) 2012-11-22
BR112013029330A2 (pt) 2016-11-29
CR20130593A (es) 2014-01-09
BR112013029330A8 (pt) 2018-01-30
TWI601537B (zh) 2017-10-11
AU2018201504A1 (en) 2018-03-22
CA2835738A1 (fr) 2012-11-22
TW201834687A (zh) 2018-10-01
TN2013000468A1 (en) 2015-03-30
IL257475A (en) 2018-06-28
KR20140043388A (ko) 2014-04-09
NZ618012A (en) 2016-03-31
AU2012258254B2 (en) 2016-04-21
IL229380A0 (en) 2014-01-30
TW201249460A (en) 2012-12-16
JP2018021020A (ja) 2018-02-08
CN103547596A (zh) 2014-01-29
PH12017501368A1 (en) 2018-01-29
US9555126B2 (en) 2017-01-31
UY34077A (es) 2013-01-03
MX2013013455A (es) 2014-02-17
ECSP13013084A (es) 2014-01-31
IL263728A (en) 2019-01-31
CN107007840A (zh) 2017-08-04
SG194894A1 (en) 2013-12-30
JP2019142961A (ja) 2019-08-29
JP2017081926A (ja) 2017-05-18
JP6181273B2 (ja) 2017-08-16
ZA201309400B (en) 2015-04-29
EA201391714A1 (ru) 2014-03-31
EP2524929A1 (fr) 2012-11-21
MY163736A (en) 2017-10-31
SG10201609729VA (en) 2016-12-29
EP2710034A1 (fr) 2014-03-26
CL2013003272A1 (es) 2014-08-01

Similar Documents

Publication Publication Date Title
MA35180B1 (fr) Utilisation d4un anticorps immunoconjugue de maytansinoide anti-cd19 pour le traitement de symptomes de malignites a lymphocytes b
MA43603A1 (fr) Récepteurs chimériques et leurs procédés d'utilisation
MA50949B1 (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
MA44594B1 (fr) Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MA39034A1 (fr) Composés de quinoline sélectivement substitués
MA44645B1 (fr) Traitement combiné d'un anticorps anti-cd20 avec un inhibiteur de bcl-2 et un inhibiteur de mdm2
MA33469B1 (fr) Polythérapie à base d'un anticorps afucosylé anti-cd20 et de bendamustine
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
MA34263B1 (fr) Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs)
MA37538B1 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
MA35173B1 (fr) Anticorps anti-cxcr4 ayant des fonctions effectrices et son utilisation pour le traitement du cancer
MA34598B1 (fr) Procédés et compositions pour traiter le cancer du poumon
MA34059B1 (fr) Thérapie anti-angiogénique pour le traitement du cancer des ovaires
MA35638B1 (fr) 2-thiopyrimidinones
SG10201807059QA (en) Agents for influenza neutralization
MX2016004167A (es) Diagnostico y tratamiento del sindrome del intestino irritable y la enfermedad inflamatoria intestinal.
MA33258B1 (fr) Utilisation de cistus libanotis pour nettoyer des sols contenant des métaux lourds
MA34489B1 (fr) Agonistes du récepteur a1 à l'adénosine destinés au traitement du glaucome et de l'hypertension oculaire
MA34291B1 (fr) Compositions et méthodes de diagnostic et de traitement d'une tumeur
MA39355B2 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
TN2016000111A1 (fr) Utilisation de l'odiparcil dans le traitement d'une mucopolysaccharidose.